AI Analysis | Feedback

Here are 1-3 brief analogies for Cencora:

• Sysco for pharmaceuticals.
• The Amazon for prescription drug distribution to hospitals and pharmacies.

AI Analysis | Feedback

• Pharmaceutical Distribution: Cencora distributes a wide range of pharmaceuticals, over-the-counter products, and healthcare supplies to hospitals, pharmacies, and other healthcare providers in the U.S. and internationally.
• Specialty Pharmaceutical Distribution: The company distributes plasma, blood products, injectable pharmaceuticals, vaccines, and other specialty products to physicians and healthcare providers specializing in various disease states.
• Animal Health Product Distribution: Cencora distributes pharmaceuticals, vaccines, diagnostics, and micro feed ingredients to the companion animal and production animal markets.
• Pharmacy Management & Consulting Services: Cencora offers pharmacy management, staffing, and other consulting services to healthcare providers.
• Supply Management Software: The company provides supply management software solutions to retail and institutional healthcare providers.
• Healthcare Packaging Solutions: Cencora offers packaging solutions for various institutional and retail healthcare providers.
• Biopharmaceutical Support Services: The company provides clinical trial support, product post-approval, and commercialization support services for biotechnology and pharmaceutical manufacturers.
• Data & Research Services: Cencora offers data analytics, outcomes research, and additional services to biotechnology and pharmaceutical manufacturers.
• Sales Force Services: The company provides sales force services to pharmaceutical manufacturers.
• Biopharmaceutical Logistics Services: Cencora offers specialty transportation and logistics services tailored for the biopharmaceutical industry.
• Global Commercialization Services: The company provides global commercialization services for pharmaceutical and healthcare products.

AI Analysis | Feedback

Cencora (COR) primarily sells to other companies and organizations within the healthcare sector, rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:

• Healthcare Providers and Facilities: This broad category includes acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physicians specializing in various disease states (such as oncology), dialysis clinics, and other health centers.
• Pharmaceutical and Biotechnology Manufacturers: Cencora provides various services to biotechnology and pharmaceutical manufacturers, including clinical trial support, product post-approval and commercialization support, data analytics, outcomes research, and sales force services. It also offers specialty transportation and logistics services for the biopharmaceutical industry.
• Animal Health Market: Cencora distributes pharmaceuticals, vaccines, parasiticides, diagnostics, and other products to customers within the companion animal and production animal markets (e.g., veterinary practices, agricultural businesses).

AI Analysis | Feedback

AI Analysis | Feedback

Robert P. Mauch, President and Chief Executive Officer

Robert P. Mauch began his more than 30-year career in pharmaceutical care as the founder of Xcenda (formerly Applied Health Outcomes), which provides health economics, strategic, and reimbursement consulting to pharmaceutical companies. He joined Cencora (formerly AmerisourceBergen) in 2007 when the company acquired Xcenda. Mauch transitioned into the role of President and Chief Executive Officer in October 2024. Prior to this, he served as Executive Vice President and Chief Operating Officer, and held various other leadership positions within the company, driving its transformation into a global provider of pharmaceutical-centered healthcare solutions.

James F. Cleary, Executive Vice President and Chief Financial Officer

James F. Cleary is Executive Vice President and Chief Financial Officer for Cencora. He joined Cencora (then AmerisourceBergen) in March 2015. Before becoming CFO in November 2018, he served as Group President, Global Commercialization Services & Animal Health. Cleary previously served as President and Chief Executive Officer of MWI Veterinary Supply, Inc. for 10 years, a company that was acquired by AmerisourceBergen in 2015. He also held management roles at Agri Beef Co. and Morrison Knudsen Corporation.

Elizabeth Campbell, Executive Vice President and Chief Legal Officer

Elizabeth Campbell is the Executive Vice President and Chief Legal Officer for Cencora, Inc. She joined the company (formerly AmerisourceBergen) in 2010 and has over 20 years of experience as a lawyer. Campbell has served in various roles with increasing responsibility, including Deputy General Counsel and Senior Vice President, overseeing legal teams for all businesses and corporate functions. Prior to joining Cencora, she worked in private practice at a large law firm.

Silvana Battaglia, Executive Vice President and Chief Human Resources Officer

Silvana Battaglia is Executive Vice President and Chief Human Resources Officer for Cencora. Before joining Cencora (formerly AmerisourceBergen) in 2019, she held senior human resources leadership roles at Aramark, where she was responsible for human capital strategy for their global workforce. Battaglia also held senior leadership positions at Day & Zimmermann and Merck. She currently serves as an independent member of the board of directors for agilon health.

Francois Mandeville, Executive Vice President, Strategy and M&A

Francois Mandeville was appointed Executive Vice President, Strategy and M&A for Cencora in November 2024. In this role, he is responsible for overseeing Cencora's mergers and acquisitions and strategy execution. Mandeville most recently served as Chief Development Officer at Johnson Controls. Prior to that, he was Senior Vice President, Strategy & Business Development at Danaher Corporation, where he was instrumental in creating strategies that significantly grew the business.

AI Analysis | Feedback

• Regulatory and Legal Risks: Cencora operates in a highly regulated industry and is exposed to ongoing legal proceedings, including significant financial settlements related to opioid litigation. The company also faces the possibility of new regulatory challenges and the need to comply with evolving data privacy regulations. Failure to navigate these issues effectively could result in substantial financial penalties, operational restrictions, and damage to its reputation.
• Cyberattacks and Data Breaches: Cencora is a target for cybercriminals due to the sensitive personal and health information it handles. The company experienced a significant cyberattack in February 2024, which resulted in unauthorized access to its information systems and the theft of personal data, including health diagnoses and prescriptions of hundreds of thousands of individuals. Such breaches can lead to substantial financial consequences and a loss of trust among customers and patients.
• Supply Chain Disruptions and Geopolitical Risks: As a global distributor of pharmaceutical products, Cencora is susceptible to events beyond its control, such as public health crises, natural disasters, and geopolitical disruptions. These challenges can significantly disrupt operations, impair supply chains, and increase costs, leading to unpredictable financial impacts. Additionally, Cencora's international operations expose it to foreign currency exchange risks and geopolitical uncertainties, which can affect its profitability and strategic objectives.

AI Analysis | Feedback

AI Analysis | Feedback

Cencora (symbol: COR) operates in several addressable markets related to pharmaceutical distribution and healthcare services. Here are the estimated market sizes for its main products and services:

• Pharmaceutical Wholesale and Distribution:
  • The global pharmaceutical wholesale and distribution market was estimated at approximately USD 1.2 trillion in 2023 and is projected to reach USD 2.1 trillion by 2032, growing at a Compound Annual Growth Rate (CAGR) of approximately 6.1%. Another estimate projects the global market to reach approximately USD 1.5 trillion by 2033, with a CAGR of 6.2% from 2025 to 2033.
  • In the U.S., the pharmaceutical market size is valued at USD 634.34 billion in 2024 and is predicted to attain around USD 1,107.4 billion by 2034, expanding at a CAGR of 5.73% from 2025 to 2034. Cencora, along with two other major players, collectively supplies over 90% of the U.S. pharmaceutical distribution market.
  • The European pharmaceutical market was valued at USD 411.94 billion in 2024 and is estimated to grow to USD 728.20 billion by 2032, exhibiting a CAGR of 7.5% during the forecast period. Another report values the Europe pharmaceutical market at USD 577.59 billion in 2025, anticipated to grow to USD 1032.76 billion by 2034, at a CAGR of 6.67%.
• Specialty Pharmaceutical Distribution and Logistics:
  • Specialty pharmaceuticals are expected to account for 70% of new medicines launched through 2027. Additionally, half of all products launched globally through 2027 are expected to require cold chain storage. In the U.S., specialty drugs account for over 50% of total drug spending.
  • The U.S. pharmaceutical logistics market, which includes specialty transportation, was estimated at USD 26.5 billion in 2023 and is projected to reach USD 45.22 billion by 2030, growing at a CAGR of 8.1% from 2024 to 2030.
  • The Europe pharmaceutical logistics market is estimated at USD 90.30 billion in 2025 and is expected to reach USD 109.44 billion by 2030, growing at a CAGR of 3.92%.
• Clinical Trial Support Services:
  • The global clinical trials support services market size was valued at USD 24.84 billion in 2024 and is poised to grow to USD 49.66 billion by 2033, at a CAGR of 8% during the forecast period (2026–2033). Another estimate places the global market size at USD 25.62 billion in 2025, projected to reach USD 47.00 billion by 2033, with a CAGR of 7.93% from 2026 to 2033.
  • North America held the largest share of the global clinical trials support services market, with more than 40% of the global revenue and a market size of USD 9805.80 million in 2025, projected to grow at a CAGR of 6.2% from 2025 to 2033.
• Data Analytics in Healthcare:
  • The global big data analytics in healthcare market size was valued at USD 56.47 billion in 2024, projected to reach approximately USD 67.32 billion by 2025, and anticipated to reach around USD 327.57 billion by 2034, growing at a CAGR of 19.21% from 2025 to 2034.
  • North America dominated the global big data analytics in healthcare market with the largest market share of 52% in 2024.
• Animal Health Product Distribution: null
• Pharmacy Management, Staffing, and Consulting Services: null

AI Analysis | Feedback

Cencora, Inc. (COR) is expected to drive future revenue growth over the next two to three years through several key strategies and market dynamics:

1. Leadership and Expansion in Specialty Pharmaceuticals: Cencora's focus on specialty pharmaceuticals, particularly in areas like oncology and retina, is a significant growth driver. This includes the impact of strategic acquisitions such as OneOncology and Retina Consultants of America (RCA), which enhance the company's specialty MSO (Management Services Organization) footprint and clinical research capabilities. The company is also capitalizing on the growth of high-demand products like GLP-1 therapies for diabetes and weight loss.
2. Robust Performance in U.S. Healthcare Solutions: The U.S. Healthcare Solutions segment consistently demonstrates strong performance and is projected to continue contributing significantly to overall revenue growth. This growth is driven by overall market expansion and sustained demand for pharmaceutical products within acute care hospitals, retail pharmacies, and other healthcare providers in the United States.
3. International Expansion and Global Commercialization Services: Cencora's International Healthcare Solutions segment is poised for continued growth, particularly in Europe. This segment benefits from its international pharmaceutical wholesale operations and its global commercialization services, which support biotechnology and pharmaceutical manufacturers in bringing products to market worldwide.
4. Strategic Investments in Distribution Network and Digital Transformation: Cencora is undertaking substantial investments, including a $1 billion commitment through 2030, to strengthen its U.S. distribution network. These investments aim to expand capacity, increase resilience, and enhance cold chain storage capabilities to support the growing volume of specialty pharmaceuticals. Furthermore, the company emphasizes digital transformation and the development of customer-centric solutions to improve operational efficiency and expand its value proposition.

AI Analysis | Feedback

Share Repurchases

• Cencora repurchased approximately $50 million of its common stock from Walgreens Boots Alliance in February 2025.
• In May 2024, Cencora repurchased approximately $400 million of its common stock from Walgreens Boots Alliance in a private transaction, contributing to roughly $550 million in total share repurchases during that month.
• In November 2022, AmerisourceBergen (now Cencora) announced its intent to repurchase approximately $500 million in shares from Walgreens Boots Alliance concurrently with a secondary public offering.

Share Issuance

• Walgreens Boots Alliance conducted secondary public offerings of Cencora (then AmerisourceBergen) common stock, including 10.5 million shares in August 2023 and 10 million shares in November 2022, from which Cencora did not receive proceeds.
• Cencora's shares outstanding have generally declined over the past three fiscal years, with decreases of 3.13% in 2023, 2.11% in 2024, and 2.53% in 2025.

Outbound Investments

• Cencora acquired the majority of outstanding equity interests it did not already own in OneOncology, a physician-led oncology platform, for approximately $4.6 billion in cash in February 2026.
• In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) with a cash outlay of $4.4 billion.
• In June 2021, the company acquired Alliance Healthcare from Walgreens Boots Alliance for $6.602 billion in cash.

Capital Expenditures

• Capital expenditures were approximately $668 million in fiscal year 2025.
• The company anticipates capital expenditures of approximately $900 million for fiscal year 2025.
• Primary focuses for capital expenditures include investments in advanced information systems, automated warehouse technology for secure supply chains, data analytics, specialty pharmacy platforms, and cold-chain logistics.